Von Hippel-Lindau Disease Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand Through 2034

The market size of Von Hippel-Lindau Disease is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Novartis Pharmaceuticals, Peloton Therapeutics Inc., Lantheus, Medical Imaging, Merck Sharp & Dohme LLC, Genentech Inc., Exelixis.

[Nevada,United States] - DelveInsight's "Von Hippel-Lindau Disease Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Von Hippel-Lindau Disease, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Von Hippel-Lindau Disease Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/von-hippel-lindau-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Von Hippel-Lindau Disease Market Report:
The Von Hippel-Lindau Disease market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
In August, 2024: Merck Sharp & Dohme LLC announced a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With hypoxia inducible factor-2 alpha (HIF-2α) related genetic alterations.
In July, 2024: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. announced that the primary objective of their study is to assess the overall response rate (ORR) of von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC) tumors in VHL participants treated with MK-3795.
In May, 2024: UNC Lineberger Comprehensive Cancer Center announced that their study is being conducted to determine if contrast-enhanced ultrasound can detect abnormal features of kidney lesions in patients with Von-Hippel Lindau with the same accuracy as conventional ultrasound and contrast-enhanced magnetic resonance imaging (MRI)
In Feb, 2024: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. announced that a Phase 2 study will evaluate the efficacy and safety of belzutifan in participants with VHL disease who have at least 1 measurable RCC tumor. Belzutifan will be administered orally and treatment will be continuous.
As per the National Cancer Institute (2021), the prevalence of VHL is estimated to be between 1 in 31,000 to 1 in 91,000 individuals.
According to Cancer.Net (2020), it is estimated that about 1 in 30,000 people have VHL. About 10% of people with VHL do not have any family history of the condition. They have a de novo mutation, meaning a new mutation in the VHL gene not present in their parents.
Key Von Hippel-Lindau Disease Companies are as follow: Novartis Pharmaceuticals, Peloton Therapeutics Inc., Lantheus, Medical Imaging, Merck Sharp & Dohme LLC, Genentech Inc., Exelixis.
Key Von Hippel-Lindau Disease Therapies: Perflutren lipid microsphere, Sulfur hexafluoride lipid microspheres, PTK787/ZK 222584, MK-3795, Belzutifan, ranibizumab injection (0.5 mg), Cabozantinib tablets, Everolimus (Afinitor) tablets.
Launching multiple stage Von Hippel-Lindau Disease pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Von Hippel-Lindau Disease market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/von-hippel-lindau-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Von Hippel-Lindau Disease Overview:
Von Hippel-Lindau (VHL) disease is an autosomal dominantly inherited disorder that demonstrates marked phenotypic variability and age-dependent penetrance. A germline mutation in the VHL gene predisposes carriers to the development of abundantly vascularized tumors in multiple organs.

Von Hippel-Lindau Disease Drugs Uptake and Pipeline Development Activities:
The drugs uptake section focuses on the rate of uptake of potential drugs recently launched or expected to be launched during the study period. The report covers market uptake by drugs, patient uptake by therapies, and sales of each drug. Additionally, it provides insights into Von Hippel-Lindau Disease Pipeline Development Activities, analyzing therapeutic candidates in various stages and key companies involved.

For more information about Von Hippel-Lindau Disease companies working in the treatment market, visit: https://www.delveinsight.com/sample-request/von-hippel-lindau-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Von Hippel-Lindau Disease Therapies and Companies:
Perflutren lipid microsphere, Sulfur hexafluoride lipid microspheres: UNC Lineberger Comprehensive Cancer Center
PTK787/ZK 222584: Novartis Pharmaceuticals
MK-3795, Belzutifan: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc.
Cabozantinib tablets, Everolimus (Afinitor) tablets: Exelixis

Von Hippel-Lindau Disease Epidemiology:
The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2020 to 2034. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Von Hippel-Lindau Disease.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/von-hippel-lindau-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Von Hippel-Lindau Disease Epidemiology Segmentation:
The Von Hippel-Lindau Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
Von Hippel-Lindau Disease Total Prevalence
Prevalent Cases of Von Hippel-Lindau Disease by severity
Gender-specific Prevalence of Von Hippel-Lindau Disease
Diagnosed Cases of Episodic and Chronic Von Hippel-Lindau Disease

Von Hippel-Lindau Disease Market Drivers and Barriers:
The Von Hippel-Lindau Disease Market Forecast report highlights key drivers and barriers shaping the Von Hippel-Lindau Disease market dynamics, providing insights into factors influencing growth and challenges that may be encountered.

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/von-hippel-lindau-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Von Hippel-Lindau Disease Market Report:
Study Period: 2020-2034
Coverage: 7MM (The United States, EU5, and Japan)
Key Von Hippel-Lindau Disease Companies: Novartis Pharmaceuticals, Peloton Therapeutics Inc., Lantheus, Medical Imaging, Merck Sharp & Dohme LLC, Genentech Inc., Exelixis.
Key Von Hippel-Lindau Disease Therapies: Perflutren lipid microsphere, Sulfur hexafluoride lipid microspheres, PTK787/ZK 222584, MK-3795, Belzutifan, ranibizumab injection (0.5 mg), Cabozantinib tablets, Everolimus (Afinitor) tablets.
Von Hippel-Lindau Disease Therapeutic Assessment: Current marketed and emerging therapies
Von Hippel-Lindau Disease Market Dynamics: Von Hippel-Lindau Disease Market drivers and Von Hippel-Lindau Disease barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Von Hippel-Lindau Disease Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Von Hippel-Lindau Disease market outlook, drug uptake, treatment scenario, and epidemiology trends: https://www.delveinsight.com/sample-request/von-hippel-lindau-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:
1 Key Insights
2 Report Introduction
3 Executive Summary
4 Key Events
5 Epidemiology and Market Forecast Methodology
6 Von Hippel-Lindau disease Market Overview at a Glance
7 Disease Background and Overview
8 Treatment and Management
9 Epidemiology and Patient Population
10 Patient Journey
11 Marketed Therapies
12 Emerging Therapies
13 Von Hippel-Lindau Disease: 7 Major Market Analysis
14 Unmet Needs
15 SWOT Analysis
16 KOL Views
17 Market Access and Reimbursement
18 Appendix
19 DelveInsight Capabilities
20 Disclaimer
21 About DelveInsight

List of TOP Selling Inhibitors Market Research Report as of 2024:

CTLA-4 Inhibitors Market: https://www.delveinsight.com/report-store/ctla4-inhibitors-market-forecast
VEGF Inhibitors Market: https://www.delveinsight.com/report-store/vegf-inhibitors-market-forecast
TROP-2 Inhibitors Market: https://www.delveinsight.com/report-store/trop2-inhibitors-market-forecast
HER2+ Market: https://www.delveinsight.com/report-store/her2-positive-market-forecast
HER3+ Market: https://www.delveinsight.com/report-store/her3-positive-market-forecast
FTase Inhibitors Market: https://www.delveinsight.com/report-store/ftase-inhibitors-market-forecast
Bispecifics Market: https://www.delveinsight.com/report-store/bispecifics-market-forecast
CAR-T Market: https://www.delveinsight.com/report-store/car-t-market-forecast
CD-19 Market: https://www.delveinsight.com/report-store/cd19-market-forecast
CD-20 Market: https://www.delveinsight.com/report-store/cd20-market-forecast
CD-38 Market: https://www.delveinsight.com/report-store/cd38-market-forecast
TP-53 Market: https://www.delveinsight.com/report-store/tp53-market-forecast
NTRK Market: https://www.delveinsight.com/report-store/ntrk-market-forecast
BRCA Market: https://www.delveinsight.com/report-store/brca-market-forecast
SMAD4/DPC4 Market: https://www.delveinsight.com/report-store/smad4-dpc4-market-forecast
Connective Tissue Growth Factor (CTGF) Inhibitors Market: https://www.delveinsight.com/report-store/connective-tissue-growth-factor-ctgf-inhibitors-market-forecast
Selective Inhibitor of the CXCR4 Chemokine Receptor Market: https://www.delveinsight.com/report-store/selective-inhibitor-of-the-cxcr4-chemokine-receptor-market-forecast
PI3K Market: https://www.delveinsight.com/report-store/pi3k-market-forecast
FGFR Market: https://www.delveinsight.com/report-store/fgfr-market-forecast
PROTAC Market: https://www.delveinsight.com/report-store/protac-market-forecast
CEACAM5 Market: https://www.delveinsight.com/report-store/ceacam5-market-forecast
Anti Cancer Vaccine Market: https://www.delveinsight.com/report-store/anti-cancer-vaccine-market-forecast
Androgen Receptor Inhibitor Market: https://www.delveinsight.com/report-store/androgen-receptor-inhibitor-market-forecast
GnRH Receptor Antagonist Market: https://www.delveinsight.com/report-store/gnrh-receptor-antagonist-market-forecast
CDK4/6 Inhibitor Market: https://www.delveinsight.com/report-store/cdk4-6-inhibitor-market-forecast
SERD Market: https://www.delveinsight.com/report-store/serd-market-forecast
AKT Inhibitor Market: https://www.delveinsight.com/report-store/akt-inhibitor-market-forecast
Radioligand Therapies Market: https://www.delveinsight.com/report-store/radioligand-therapies-market-forecast
B7-H3 Market: https://www.delveinsight.com/report-store/b7-h3-market-forecast
CYP17 Inhibitor Market: https://www.delveinsight.com/report-store/cyp17-inhibitor-market-forecast
NTD AR Inhibitor Market: https://www.delveinsight.com/report-store/ntd-ar-inhibitor-market-forecast
NRG fusion Market: https://www.delveinsight.com/report-store/nrg-fusion-market-forecast
AXL Receptor Tyrosine Kinase Inhibitors Market: https://www.delveinsight.com/report-store/axl-receptor-tyrosine-kinase-inhibitors-market-forecast
PSMA-Targeted Therapy Market: https://www.delveinsight.com/report-store/psma-targeted-therapy-market-forecast
EGFR Market: https://www.delveinsight.com/report-store/egfr-market-forecast
ALK Market: https://www.delveinsight.com/report-store/alk-market-forecast
BRAF Market: https://www.delveinsight.com/report-store/braf-market-forecast
ERBB 2 Receptor Antagonists Market: https://www.delveinsight.com/report-store/erbb2-receptor-antagonists-market-forecast
VEGFR-2 Inhibitor Market: https://www.delveinsight.com/report-store/vegfr2-inhibitor-market-forecast
Thymidine Phosphorylase Inhibitors Market: https://www.delveinsight.com/report-store/thymidine-phosphorylase-inhibitors-market-forecast
DNA Synthesis Inhibitor Market: https://www.delveinsight.com/report-store/dna-synthesis-inhibitor-market-forecast
CD223 Antigen Inhibitors Market: https://www.delveinsight.com/report-store/cd223-antigen-inhibitors-market-forecast
BTK Inhibitors Market: https://www.delveinsight.com/report-store/btk-inhibitors-market-forecast
SERMS Market: https://www.delveinsight.com/report-store/serms-market-forecast
PLK1 Inhibitor Market: https://www.delveinsight.com/report-store/plk1-inhibitor-market-forecast
CD47 Antigen Inhibitors Market: https://www.delveinsight.com/report-store/cd47-antigen-inhibitors-market-forecast
RET Fusion Market: https://www.delveinsight.com/report-store/ret-fusion-market-forecast
ROS-1 Market: https://www.delveinsight.com/report-store/ros1-market-forecast
Mesenchymal-epithelial Transition Factor (MET) Market: https://www.delveinsight.com/report-store/mesenchymal-epithelial-transition-factor-met-market-forecast
MET Kinase Inhibitor Market: https://www.delveinsight.com/report-store/met-kinase-inhibitor-market-forecast

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.